International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Commentary: Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.

image of computer with words expert commentary

Peter van de Kerkhof, MD, PhD

IPC Chief Medical Officer
The Netherlands

Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G, R. Journal of the American Academy of Dermatology (2020), DOI: https://doi.org/10.1016/ j.jaad.2020.04.085.

COMMENTARY

The treatment of patients with psoriasis has been challenged by the COVID 19 pandemic. In March 2020, with a lack of data allowing an evidence-based approach, IPC formulated a statement urging physicians to discontinue immunosuppressive treatments in patients with active COVID-19 disease.  For psoriasis patients with no signs or symptoms of COVID-19, decisions about continuing treatment needed to be taken on a case by case basis, balancing risk with benefit.

I would like to draw your attention to a publication by Paulo Gisondi from Verona on the risk of hospitalization and death from COVID-19 in psoriatic patients receiving biological treatments (980 patients) and renal transplant recipients on immunosuppressive treatment (247 patients).

No psoriatic patients were hospitalized or died for the reason of COVID 19 and only one kidney transplant recipient died. In the general population of Verona, 0.28% of the COVID-19 patients were hospitalized or died. The average age of the patients with psoriasis and renal transplant recipients was 56 and 57 years respectively.  39 % of the psoriasis patients were obese and 12% had diabetes and cardiovascular disease. The authors indicated several limitations of the study.  Nevertheless, the study provides important early information.

At present dermatologists are collecting information in COVID registries. IPC is pleased to be a partner on the PsoProtect registry for psoriasis and COVID-19 positive patients. Please consider submitting a case or cases to the registry as it is of utmost importance that we collect the data from patients with psoriasis suffering from COVID-19.

Disclaimer: Views expressed in this commentary are those of the author and do not necessarily represent the position of the International Psoriasis Council or its Board of Directors.

Categories

Recent Posts

New IPC Guidelines on Generalized Pustular Psoriasis

Commentary: An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

Introducing our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Also Read

Generalized Pustular Psoriasis

New IPC Guidelines on Generalized Pustular Psoriasis

Learn about the new global diagnostic criteria for Generalized Pustular Psoriasis as set by the International Psoriasis Council. Discover the essential features, the importance of accurate diagnosis, and the expected global impact on patient care.

Read More
dermatology innovations

Focus on Psoriasis: A Report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV)

Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in Berlin, Germany. This report covers significant updates on psoriasis, including the International Psoriasis Council’s Symposium and late-breaking sessions. Download the full EADV Congress Report for a comprehensive overview of psoriasis presentation and treatment advancements.

Read More
Blog - Commentary - Alexander Egeberg - graphic
long-term treatment

Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares

Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.